The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...

RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.

The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.

GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of ...

GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0 ...

London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Results from the REVISIT trial show aztreonam-avibactam had similar cure rates as meropenem in patients with serious ...

October is RSV Awareness Month and GSK’s Dr. Leonard Friedland is here to tell you what you need to know about this ...

Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...

PHILADELPHIA, PA, USA I October 08, 2024 I GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III ...

Eric Mbonigaba recovered from mpox after four weeks in hospital but the Burundian motorcycle taxi driver says he has since ...